ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY

Дата публикации: 27-08-2026 00:00:00

ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	0	5	27-08-2026
2	Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors	0	5.21	27-08-2026
3	PHASE 1B TRIAL OF AVL-292, A COVALENT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-NON-HODGKIN LYMPHOMA (B-NHL)	0	6.62	27-08-2026
4	RANDOMIZED COMPARISON OF IBRUTINIB <i>VERSUS</i> OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL	0	2.29	27-08-2026
5	Celltrion Becomes First to Acquire U.S. Interchangeability Status for Truxima	0	9.51	01-07-2026
6	Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL	0	2.16	27-08-2026
7	Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis	0	2.5	27-08-2026
8	MICRORNA MIR-150 CONTRIBUTES TO THE DISEASE AGGRESSIVENESS AND REGULATION OF B-CELL RECEPTOR SIGNALLING (BCR) IN CLL	0	5.63	27-08-2026
9	FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma	0	12.93	10-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 2.3. Источник: escholarship.org.